Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Open and Active Clinical Trials on Epithelial Ovarian Cancer1
This appendix includes a listing of the clinical trials in epithelial ovarian cancer that are open and recruiting, open and not yet recruiting (denoted by an asterisk), or active but closed to recruiting as of the writing of this report. The data in this table were generated by a search performed on www.ClinicalTrials.gov on December 4, 2015, using the subtopic of “epithelial ovarian cancer.” Studies with an “unknown” status have been excluded. This search resulted in 204 interventional studies and 31 observational studies. The studies are presented in the following table by study phase and by study type (interventional versus observational). The table lists the types of interventions used in each study, but does not include placebos (where used), nor the different types of administration of the same intervention (e.g., different dosage amounts of the same drug).
The purpose of this appendix is to give a broader sense of the types of studies that are under way as well as to give a sense of the priority areas of focus. This appendix is not intended to serve as an exhaustive list of all studies currently under way in ovarian cancer. The committee also acknowledges that many of these studies are not limited to ovarian cancers. Furthermore, the committee acknowledges that by limiting the list to studies that specifically target epithelial ovarian cancers, the many more studies being performed on ovarian cancers in general are excluded. A similar search done under the subtopic of ovarian cancer in general revealed 385 open studies and 223 studies that are closed and active but not recruiting. These numbers likely include the studies listed in this appendix.
________________
1 Open trials listed on www.ClinicalTrials.gov as of December 4, 2015.
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| Phase I Interventional Studies | ||
| NCT01536054 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II–IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Sirolimus |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | Temsirolimus; vinorelbine ditartrate |
| NCT00357448 | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | N/A |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Bortezomib; carboplatin |
| NCT01322802 | Vaccine Therapy in Treating Patients With Stage III–IV or Recurrent Ovarian Cancer | N/A |
| NCT00436254 | Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With HER-2 Positive Stage III–IV Breast Cancer or Ovarian Cancer | N/A |
| NCT02046421 | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Mifepristone; carboplatin; gemcitabine hydrochloride |
| NCT00602277 | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy | N/A |
| NCT01715168 | A Crossover Bioequivalence Study of Intravenously Administered ATI-0918 and DOXIL/CAELYX in Patients With Ovarian Cancer | DOXIL/CAELYX; ATI-0918 |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sargramostim | Laboratory biomarker analysis (LBA) | 7 | Roswell Park Cancer Institute; National Cancer Institute (NCI); Sanofi Pasteur, a Sanofi Company |
| N/A | N/A | 19 | University of Southern California; Wyeth (now a wholly owned subsidiary of Pfizer) |
| Denileukin diftitox | LBA; intraperitoneal (IP) administration; enzyme-linked immunosorbent assay; flow cytometry | 11 | University of Washington; NCI |
| N/A | LBA; pharmacological study | 36 | NCI |
| pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine | LBA | 22 | University of Washington; NCI |
| pNGVL3-hICD vaccine; sargramostim | Flow cytometry; immunologic technique; immunoenzyme technique; protein expression analysis; biopsy | 66 | University of Washington; NCI |
| N/A | LBA; pharmacological study | 22 | University of Chicago; NCI |
| Wild-type reovirus | LBA | 14 | NCI |
| N/A | N/A | 40 | Azaya Therapeutics, Inc. |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01940172 | Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer | Birinapant; conatumumab |
| NCT01459380 | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Carboplatin; pegylated liposomal doxorubicin hydrochloride; veliparib |
| NCT02270372 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | N/A |
| NCT00562640 | Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | Cyclophosphamide |
| NCT00408590 | Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer, or Primary Peritoneal Cancer | N/A |
| NCT02159716 | CART-meso in Mesothelin Expressing Cancers | N/A |
| NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | MEK162, MEK inhibitor (oral); paclitaxel, mitotic inhibitor (intravenous) |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | N/A | 40 | TetraLogic Pharmaceuticals |
| Bevacizumab | LBA | 48 | NCI |
| ONT-10, varlilumab combination | N/A | 42 | Oncothyreon, Inc.; Celldex Therapeutics |
| Filgrastim; therapeutic autologous lymphocytes | LBA | 21 | Memorial Sloan Kettering Cancer Center; NCI |
| Carcinoembryonic antigen-expressing measles virus; oncolytic measles virus encoding thyroidal sodium iodide symporter reaction | LBA; reverse transcriptase-polymerase chain | 46 | Mayo Clinic; NCI |
| CART-meso | N/A | 21 | Abramson Cancer Center of the University of Pennsylvania |
| N/A | N/A | 36 | Array BioPharma |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01121640 | A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women | N/A |
| NCT01286987 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | BMN 673 |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II–III Breast or Stage II–IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Cyclophosphamide |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | Sirolimus |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | Veliparib |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy | Veliparib |
| NCT00410553 | Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery | Eribulin mesylate; gemcitabine hydrochloride |
| NCT01220154 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | Bevacizumab; paclitaxel; carboplatin |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | CA-125 assay on Abbott Architect i1000SR platform; HE4 assay on Architect i1000SR platform; transvaginal ultrasound | 1,208 | Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research; Canary Foundation; Swedish Medical Center; Beckman Research Institute; Cedars-Sinai Medical Center; Stanford University; Fox Chase Cancer Center |
| N/A | N/A | 113 | BioMarin Pharmaceutical |
| Multi-epitope folate receptor alpha peptide vaccine | LBA | 24 | Mayo Clinic; NCI |
| DEC-205/NY-ESO-1 fusion protein CDX-1401 | LBA; pharmacological study | 30 | Roswell Park Cancer Institute; NCI |
| N/A | LBA; quality-of-life (QOL) assessment; radiation therapy | 40 | NCI |
| N/A | LBA; pharmacological study | 120 | NCI |
| N/A | N/A | 45 | NCI |
| N/A | N/A | 9 | David O’Malley; Genentech, Inc.; Ohio State University Comprehensive Cancer Center |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01314105 | BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma, or Primary Peritoneal Cancer | BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min |
| NCT00825201 | Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | Paclitaxel albumin-stabilized nanoparticle formulation |
| NCT00652691 | Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer | Carboplatin; cyclophosphamide; topotecan hydrochloride |
| NCT01445418 | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | AZ2281 + carboplatin |
| NCT02083536* | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | Docetaxel |
| NCT02275039* | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Gemcitabine hydrochloride |
| NCT01489371* | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Pegylated liposomal doxorubicin hydrochloride |
| NCT01249443* | Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | Vorinostat; carboplatin; paclitaxel |
| NCT02606305* | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin, or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | IMGN853; bevacizumab; carboplatin; doxorubicin |
| NCT02260544* | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection | Doxorubicin hydrochloride liposome injection |
| NCT02014337* | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Mifepristone and eribulin in combination |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | N/A | 19 | Boehringer Ingelheim |
| N/A | Liquid chromatography; mass spectrometry; pharmacological study; LBA | 29 | City of Hope Medical Center; NCI; National Comprehensive Cancer Network |
| Filgrastim | Autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation | 48 | Mayo Clinic; NCI |
| N/A | N/A | 103 | NCI; National Institutes of Health Clinical Center (CC) |
| N/A | Low-dose fractionated whole abdominal radiation therapy | 12 | University of Miami |
| Modified vaccinia virus ankara vaccine expressing p53 | LBA | 9 | City of Hope Medical Center; NCI |
| EGEN-001 | LBA | 18 | Gynecologic Oncology Group; NCI |
| N/A | Diagnostic LBA; pharmacological study | 26 | AIDS Malignancy Consortium; NCI; The EMMES Corporation |
| N/A | N/A | 145 | ImmunoGen, Inc. |
| N/A | N/A | 48 | Dr. Reddy’s Laboratories Limited |
| N/A | N/A | 40 | Corcept Therapeutics |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT02083536* | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | Docetaxel |
| NCT02275039* | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Gemcitabine hydrochloride |
| NCT01489371* | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Pegylated liposomal doxorubicin hydrochloride |
| NCT01249443* | Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | Vorinostat; carboplatin; paclitaxel |
| NCT02606305* | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | IMGN853; bevacizumab; carboplatin; doxorubicin |
| NCT02260544* | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection | Doxorubicin hydrochloride liposome injection |
| NCT02014337* | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Mifepristone and eribulin in combination |
| NCT02520115* | Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples from Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | Dexamethasone; valproic acid |
| NCT01281514* | Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Everolimus; carboplatin; pegylated liposomal doxorubicin hydrochloride |
| NCT02480374* | Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer | N/A |
| NCT02324439* | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | N/A |
| NCT02312661* | Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer | Metformin; paclitaxel; carboplatin |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | Low-dose fractionated whole abdominal radiation therapy | 12 | University of Miami |
| Modified vaccinia virus ankara vaccine expressing p53 | LBA | 9 | City of Hope Medical Center; NCI |
| EGEN-001 | LBA | 18 | Gynecologic Oncology Group; NCI |
| N/A | Diagnostic LBA; pharmacological study | 26 | AIDS Malignancy Consortium; NCI; The EMMES Corporation |
| N/A | N/A | 145 | ImmunoGen, Inc. |
| N/A | N/A | 48 | Dr. Reddy’s Laboratories Limited |
| N/A | N/A | 40 | Corcept Therapeutics |
| N/A | LBA | 180 | Barbara Ann Karmanos Cancer Institute; NCI |
| N/A | 24 | Fox Chase Cancer Center | |
| GEN-1 | N/A | 15 | Celsion |
| N/A | Omega Nutrition cold-milled flaxseeds | 90 | Southern Illinois University |
| N/A | N/A | 20 | University Medical Center Groningen |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT02534922* | Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer | N/A |
| NCT02470559* | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Is Stage III–IV, Refractory, or Recurrent | N/A |
| NCT02432963* | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | N/A |
| NCT02298959* | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | N/A |
| NCT02142803* | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | TORC1/2 inhibitor INK128 |
| NCT01145430* | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | Pegylated liposomal doxorubicin hydrochloride; veliparib |
| NCT02344095* | A Trial of Weekly Paclitaxel With Oncothermia and Weekly Cisplatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | Weekly paclitaxel; weekly cisplatin |
| NCT00989651* | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II–IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Carboplatin; cisplatin; paclitaxel; veliparib |
| NCT02199171* | Heated Carboplatin in Treating Patients With Stage II–IV Ovarian, Fallopian Tube, or Peritoneal Cancer | Carboplatin |
| NCT01665183* | Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma | ADI-PEG 20 |
| NCT02000778* | EC17 for Intraoperative Imaging in Occult Ovarian Cancer | EC17 |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| Prolanta, a human prolactin receptor antagonist | N/A | 18 | Oncolix, Inc. |
| Aldesleukin; HER2Biarmed activated T cells; sargramostim | LBA | 20 | Barbara Ann Karmanos Cancer Institute; NCI |
| Modified vaccinia virus ankara vaccine expressing p53; pembrolizumab | LBA | 12 | City of Hope Medical Center; NCI |
| Pembrolizumab; ziv-aflibercept | LBA | 36 | NCI |
| Bevacizumab | LBA; pharmacological study | 60 | NCI |
| N/A | LBA; pharmacological study | 58 | NCI |
| N/A | Oncothermia | 12 | Seoul National University Hospital |
| Bevacizumab | LBA | 474 | NCI |
| N/A | N/A | 30 | University of California, Irvine |
| N/A | N/A | 89 | Polaris Group |
| N/A | N/A | 10 | University of Pennsylvania |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT02530047* | Mesenchymal Stem Cells (MSC) for Ovarian Cancer | N/A |
| NCT02303912* | Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer | Nuc-1031; carboplatin |
| NCT02534922* | Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer | N/A |
| NCT02627430* | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | HSP90 inhibitor AT13387; talazoparib |
| NCT02530047* | Mesenchymal Stem Cells (MSC) for Ovarian Cancer | N/A |
| Phase I/II Interventional Studies | ||
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | Cyclophosphamide; poly ICLC |
| NCT01472783 | Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation | Veliparib |
| NCT01091428 | MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | MLN8237 + paclitaxel |
| NCT01238770 | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Pazopanib |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | Topotecan; gefitinib |
| NCT02244502* | Safety, Feasibility, and Effect of TTFields Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma | Paclitaxel |
| NCT01709487* | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First-Line Therapy | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | MSC-INFβ; questionnaires | 21 | MD Anderson Cancer Center |
| N/A | N/A | 36 | Imperial College Healthcare NHS Trust |
| Prolanta, a human prolactin receptor antagonist | N/A | 18 | Oncolix, Inc. |
| N/A | LBA; pharmacological study | 40 | NCI |
| MSC-INFβ | Questionnaires | 21 | MD Anderson Cancer Center |
| N/A | Hepatic artery embolization; 3-dimensional conformal radiation therapy | 50 | Rutgers, The State University of New Jersey |
| N/A | N/A | 49 | Vejle Hospital; Abbott |
| N/A | N/A | 172 | Millennium Pharmaceuticals, Inc. |
| N/A | N/A | 57 | Priv.-Doz. Dr. med. Joachim Rom; University Hospital Heidelberg |
| N/A | N/A | 52 | MD Anderson Cancer Center; AstraZeneca; GlaxoSmithKline |
| N/A | NovoTTF-100L(O) (device) | 30 | NovoCure, Ltd. |
| N/A | Hyperthermic intraperitoneal chemotherapy (HIPEC) | 24 | Jules Bordet Institute |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01631552* | Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers | IMMU-132 |
| NCT01962948* | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Paclitaxel; ganetespib |
| NCT02068794* | MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer | N/A |
| NCT01402271* | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Carboplatin; paclitaxel; pazopanib hydrochloride |
| NCT02584478* | A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 to Standard Platinum-Based Chemotherapy | AL3818; carboplatin; paclitaxel |
| NCT02335918* | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Combination of varlilumab and nivolumab |
| NCT02166905* | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Poly ICLC; IDO1 inhibitor INCB024360 |
| NCT02012192* | GANNET53: Ganetespib in Metastatic, p53Mutant, Platinum-Resistant Ovarian Cancer | Ganetespib; paclitaxel |
| NCT01663857* | A Study of LY2228820 for Recurrent Ovarian Cancer | LY2228820; carboplatin; gemcitabine |
| NCT01116648* | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Cediranib maleate; olaparib |
| NCT02028117* | Phase I/II Study of Enadenotucirev Intraperitoneally in Ovarian Cancer Patients | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | N/A | 250 | Immunomedics, Inc. |
| N/A | LBA | 74 | Fox Chase Cancer Center; NCI |
| Oncolytic measles virus encoding thyroidal sodium iodide symporter | LBA; mesenchymal stem cell transplantation | 54 | Mayo Clinic; NCI |
| N/A | LBA; pharmacological study | 96 | European Organisation for Research and Treatment of Cancer (EORTC) |
| N/A | N/A | 48 | Advenchen Laboratories, LLC |
| N/A | N/A | 190 | Celldex Therapeutics; Bristol-Myers Squibb |
| DEC-205/NY-ESO-1 fusion protein CDX-1401 | LBA; pharmacological study | 98 | Roswell Park Cancer Institute; NCI; Celldex Therapeutics |
| N/A | N/A | 222 | Medical University Innsbruck; European Commission |
| N/A | N/A | 116 | Eli Lilly and Company |
| N/A | LBA; pharmacological study | 162 | NCI |
| Enadenotucirev | N/A | 35 | PsiOxus Therapeutics, Ltd |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT02354131* | Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum-Sensitive Ovarian Cancer | Niraparib; bevacizumab |
| NCT02098343* | p53 Suppressor Activation in Recurrent High-Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | APR-246; carboplatin; pegylated liposomal doxorubicin hydrochloride |
| Phase II Interventional Studies | ||
| NCT02107950 | Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma | Standard of care chemotherapy |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | N/A |
| NCT02107378 | Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma | Standard of care (paclitaxel or topotecan or doxorubicin) |
| NCT01118052 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | N/A |
| NCT00679783 | Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High-Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/Triple Neg Breast Cancer | AZD2281 |
| NCT00993655 | Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Carboplatin; cisplatin; paclitaxel |
| NCT00979992 | Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer | Sunitinib malate |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | N/A | 147 | Nordic Society for Gynaecologic Oncology; ENGOT; GCIG; Stanford University |
| N/A | N/A | Null | Aprea AB |
| DCVAC/OvCa | N/A | 60 | Sotio a.s. |
| Rilotumumab | Diagnostic LBA | 50 | Gynecologic Oncology Group; NCI |
| DCVAC/OvCa | N/A | 60 | Sotio a.s. |
| EGEN-001 | LBA | 56 | Gynecologic Oncology Group; NCI |
| N/A | N/A | 112 | AstraZeneca; British Columbia Cancer Agency |
| N/A | QOL assessment | 275 | NCIC Clinical Trials Group; NCI; Grupo Español de Investigación en Cáncer de Ovario; Cancer Research UK; Southwest Oncology Group |
| N/A | LBA | 53 | NCI |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT00538031 | Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Cyclophosphamide; celecoxib |
| NCT00278343 | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | Cediranib maleate |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Everolimus; letrozole |
| NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Pegylated liposomal doxorubicin (PLD); VTX-2337 |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | Avastin |
| NCT00872989 | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Docetaxel; vandetanib |
| NCT01097746 | First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer | Carboplatin; paclitaxel; bevacizumab |
| NCT01720173 | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | N/A |
| NCT01716715 | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Cabozantinib S-malate; paclitaxel |
| NCT01540565 | Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Veliparib |
| NCT01468909 | Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Paclitaxel; pazopanib hydrochloride |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | N/A | 27 | City of Hope Medical Center |
| N/A | LBA | 74 | NCI |
| N/A | LBA | 20 | Mayo Clinic; NCI |
| N/A | N/A | 290 | VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group |
| N/A | N/A | 22 | University of Oklahoma; Genentech, Inc. |
| N/A | N/A | 120 | Southwest Oncology Group; NCI |
| N/A | N/A | 30 | MD Anderson Cancer Center; Genentech, Inc. |
| Dalantercept | LBA | 56 | Gynecologic Oncology Group; NCI |
| N/A | LBA | 102 | NCI |
| N/A | LBA | 51 | NCI |
| N/A | LBA | 110 | NCI |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01305213 | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Fosbretabulin tromethamine |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Paclitaxel |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | Temsirolimus |
| NCT02324595 | Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: A Feasibility Study | N/A |
| NCT01991210 | A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer | DNIB0600A; pegylated liposomal doxorubicin |
| NCT00857545 | OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission | N/A |
| NCT00744718 | Bevacizumab and Carboplatin for Patients With Ovarian Cancer | Bevacizumab; carboplatin |
| NCT00551070 | Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | Selumetinib |
| NCT01460979 | Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma | Temsirolimus |
| NCT00373217 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Carboplatin; paclitaxel |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| Bevacizumab | LBA | 110 | NCI |
| Wild-type reovirus | LBA | 110 | NCI |
| Bevacizumab | N/A | 299 | NCI |
| N/A | Laparoscopic interval debulking surgery | 30 | Catholic University of the Sacred Heart; Fagotti, Anna, M.D.; Francesco Fanfani; Salvatore Gueli Alletti |
| N/A | N/A | 95 | Genentech, Inc. |
| Immunoadjuvant OPT-821; polyvalent antigen-KLH conjugate vaccine | LBA | 164 | Gynecologic Oncology Group; NCI |
| N/A | N/A | 30 | Vejle Hospital |
| N/A | LBA; pharmacological study | 52 | NCI |
| N/A | N/A | 86 | AGO Study Group |
| MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine; tetanus toxoid helper peptide | Conventional surgery | 28 | Craig L Slingluff, Jr.; NCI; University of Virginia |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01551745 | Salvage Ovarian FANG™ Vaccine + Bevacizumab | Bevacizumab |
| NCT01439659 | Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer | N/A |
| NCT01309230 | Trial of Adjuvant FANG™ Vaccine for High-Risk Stage III/IV Ovarian Cancer | N/A |
| NCT02435186* | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | p53 gene; cisplatin; paclitaxel |
| NCT02107937* | Phase II Study DCVAC/OvCa Added to First-Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | Standard of care |
| NCT01764802* | Psychosexual Intervention in Patients With Stage I–III Gynecologic or Breast Cancer | N/A |
| NCT02122185* | Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III–IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Paclitaxel; carboplatin; docetaxel; metformin hydrochloride |
| NCT00888615* | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Elesclomol sodium; paclitaxel |
| NCT02584465* | REGorafenib vs. Tamoxifen in Patients With Platinum-Sensitive Ovarian Carcinoma and Isolated Biological Progression | Tamoxifen; regorafenib |
| NCT02487849* | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-Sensitive Recurrence of Ovarian Carcinoma | Carboplatin |
| NCT01899599* | PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer | PankoMab-GEX |
| NCT02033616* | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Advanced Epithelial Ovarian Carcinomas | N/A |
| NCT02487693* | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Patients With Ovarian Carcinoma | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| Vigil™ vaccine | N/A | 5 | Gradalis, Inc. |
| N/A | Nutritional counseling; daily supplements | 75 | MD Anderson Cancer Center; Natural Alternatives International |
| Vigil™ | N/A | 44 | Gradalis, Inc. |
| N/A | N/A | 100 | Shenzhen SiBiono; GeneTech Co., Ltd. |
| DCVAC/OvCa | N/A | 90 | Sotio a.s. |
| N/A | Behavioral, psychological, or informational intervention | 100 | Ohio State University Comprehensive Cancer Center; NCI |
| N/A | LBA | 160 | University of Chicago; NCI |
| N/A | N/A | 55 | Gynecologic Oncology Group; NCI |
| N/A | N/A | 116 | ARCAGY/GINECO GROUP; Bayer |
| N/A | HIPEC | 10 | Krankenhaus Barmherzige Schwestern Linz |
| N/A | N/A | 210 | Glycotope GmbH |
| Ovapuldencel-T; MC: autologous PBMCs in GM-CSF | N/A | 99 | Caladrius Biosciences, Inc. |
| Cytokine-induced killer cells | Radiofrequency ablation | 50 | The First People’s Hospital of Changzhou |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT02437812* | Study of Paclitaxel, Carboplatin, and Oral Metformin in the Treatment of Advanced-Stage Ovarian Carcinoma | Metformin; paclitaxel; carboplatin |
| NCT01735071* | Bevacizumab and Trabectedin +/–Carboplatin in Advanced Ovarian Cancer | Bevacizumab; trabectedin; carboplatin |
| NCT02315430* | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Cabozantinib S-malate |
| NCT02569957* | Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High-Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Topotecan hydrochloride; acetylcysteine |
| NCT02124421* | Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Adjuvant chemotherapy; carboplatin; paclitaxel; cisplatin |
| NCT02364713* | MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Pegylated liposomal doxorubicin hydrochloride; gemcitabine hydrochloride; topotecan hydrochloride; paclitaxel |
| NCT02101775* | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Gemcitabine hydrochloride; WEE1 inhibitor AZD1775 |
| NCT02125513* | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer | Carboplatin; paclitaxel |
| NCT02025985* | Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies & Metastatic Breast Cancer | Selinexor |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | N/A | 30 | Gynecologic Oncology Associates; University of North Carolina at Chapel Hill |
| N/A | N/A | 74 | Mario Negri Institute for Pharmacological Research; PharmaMar; Hoffmann-La Roche |
| N/A | LBA | 34 | NCI |
| N/A | N/A | 48 | Thomas Jefferson University; NIH |
| N/A | Cytoreductive surgery; questionnaire; HIPEC | 48 | Mercy Medical Center |
| Oncolytic measles virus encoding thyroidal sodium iodide symporter | LBA; QOL assessment | 134 | Mayo Clinic; NCI |
| N/A | LBA; pharmacological study | 100 | NCI |
| N/A | Surgery | 220 | Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi |
| N/A | N/A | 105 | Karyopharm Therapeutics, Inc. |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01936974* | (PGA) for Platinum-Resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | Gemcitabine; bevacizumab; carboplatin; cisplatin; oxaliplatin |
| NCT02595021* | Total/Subtotal Colectomy in Ovarian Cancer | N/A |
| NCT01891344* | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Oral rucaparib |
| NCT01536743* | A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression | PD0332991 |
| NCT02595892* | Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | ATR kinase inhibitor VX-970; gemcitabine hydrochloride |
| NCT02345265* | Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | Cediranib maleate; olaparib |
| NCT02312245* | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Gemcitabine hydrochloride; paclitaxel; pegylated liposomal doxorubicin hydrochloride; topotecan hydrochloride |
| NCT02059265* | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial, or Peritoneal Cancer | Dasatinib |
| NCT01853644* | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Tivozanib |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | N/A | 88 | Western Regional Medical Center |
| N/A | Total or subtotal colectomy; other bowel resection | 80 | Shanghai Gynecologic Oncology Group; Shanghai Zhongshan Hospital |
| N/A | N/A | 480 | Clovis Oncology, Inc.; Foundation Medicine |
| N/A | N/A | 30 | Jonsson Comprehensive Cancer Center |
| N/A | LBA | 70 | NCI |
| N/A | LBA; pharmacological study | 70 | NCI |
| N/A | N/A | 60 | Mayo Clinic; NCI |
| N/A | LBA | 62 | NCI |
| N/A | N/A | 30 | Northwestern University; National Comprehensive Cancer Network |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01669226* | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer | PEip (weekly) and TCiv; TCiv |
| NCT01669798* | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | BIBF 1120 |
| NCT02135523* | The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial | N/A |
| NCT02435186* | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | p53 gene; cisplatin; paclitaxel |
| NCT02487849* | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-Sensitive Recurrence of Ovarian Carcinoma | Carboplatin |
| NCT02033616* | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Advanced Epithelial Ovarian Carcinomas | N/A |
| NCT02631876* | PH2 Study of IMGN853 vs. Investigator’s Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal, or Primary Fallopian Tube Cancer | IMGN853; paclitaxel; doxorubicin; gemcitabine; topotecan |
| NCT02487693* | Radiofrquency Ablation Combined With Cytokine-Induced Killer Cells for the Patients With Ovarian Carcinoma | N/A |
| NCT02627443* | Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | ATR kinase inhibitor VX-970; carboplatin; gemcitabine hydrochloride |
| NCT02595892* | Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | ATR kinase inhibitor VX-970; gemcitabine hydrochloride |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | N/A | 200 | Shanghai Gynecologic Oncology Group; Fudan University; Shanghai Jiao Tong University School of Medicine; Shanghai Zhongshan Hospital |
| N/A | N/A | 56 | AA Secord; Boehringer Ingelheim; Duke University |
| N/A | Involved-field radiation therapy | 70 | Yonsei University |
| N/A | N/A | 100 | Shenzhen SiBiono GeneTech Co., Ltd. |
| N/A | HIPEC | 10 | Krankenhaus Barmherzige Schwestern Linz |
| Ovapuldencel-T; MC: autologous PBMCs in GM-CSF | N/A | 99 | Caladrius Biosciences, Inc. |
| N/A | N/A | 247 | ImmunoGen, Inc. |
| Cytokine-induced killer cells | Radiofrequency ablation | 50 | The First People’s Hospital of Changzhou |
| N/A | LBA; pharmacological study | 117 | NCI |
| N/A | LBA | 70 | NCI |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| Phase II/III Interventional Studies | ||
| NCT02101788* | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | Letrozole; paclitaxel; pegylated liposomal doxorubicin hydrochloride; tamoxifen citrate; topotecan hydrochloride; trametinib |
| NCT02502266* | Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Cediranib maleate; olaparib; paclitaxel; pegylated liposomal doxorubicin hydrochloride; topotecan hydrochloride |
| NCT01506856* | Intraperitoneal Therapy for Ovarian Cancer With Carboplatin Trial | IV paclitaxel + IV carboplatin; IV paclitaxel + IP carboplatin |
| Phase III Interventional Studies | ||
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II–III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Carboplatin; cisplatin; paclitaxel |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Carboplatin; paclitaxel |
| NCT01081262 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II–IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | Capecitabine; carboplatin; oxaliplatin; paclitaxel |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | Paclitaxel; carboplatin; ifosfamide |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | LBA; pharmacological study; QOL assessment | 250 | NCI |
| N/A | LBA; questionnaire administration | 680 | NCI |
| N/A | N/A | 654 | Gynecologic Oncology Trial & Investigation Consortium; Japanese Gynecologic Oncology Group |
| Bevacizumab | LBA; QOL assessment | 1500 | NCI |
| Bevacizumab | Computed tomography; therapeutic conventional surgery | 650 | NCI |
| Bevacizumab | LBA; QOL assessment | 332 | NCI |
| N/A | QOL assessment | 603 | Gynecologic Oncology Group; NCI |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT00108745 | Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer | Paclitaxel poliglumex; paclitaxel |
| NCT00305851 | Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant | N/A |
| NCT01684878 | A Study of Pertuzumab in Combination With Standard Chemotherapy in Women With Recurrent Platinum-Resistant Epithelian Ovarian Cancer and Low HER3 mRNA Expression | Chemotherapy; pertuzumab |
| NCT01376349 | Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms | Prasterone |
| NCT01837251 | Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | Carboplatin; PLD |
| NCT01462890 | Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer | Paclitaxel; carboplatin |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | AMG386; PLD |
| NCT00719303* | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | Clinical observation | 1,100 | Gynecologic Oncology Group; NCI |
| N/A | Music therapy (books on tape); psychosocial assessment and care; QOL assessment; music video | 118 | Children’s Oncology Group; NCI; National Institute of Nursing Research (NINR) |
| N/A | N/A | 208 | Hoffmann-La Roche |
| N/A | N/A | 464 | Alliance for Clinical Trials in Oncology; NCI; Mayo Clinic |
| Bevacizumab | N/A | 682 | AGO Research GmbH; Arbeitsgemeinschaft Gynaekologische Onkologie Austria; ARCAGY/GINECO GROUP; ANZGOG; Scottish Gynaecological Cancer Study Group |
| Bevacizumab | Specialized pathology review E182 (Germany only) | 800 | AGO Study Group; ARCAGY/GINECO GROUP; Nordic Society for Gynaecologic Oncology |
| N/A | N/A | 223 | Amgen |
| N/A | Behavioral dietary intervention; compliance monitoring; counseling; educational intervention; exercise intervention; LBA; QOL assessment; questionnaire administration | 1,070 | Gynecologic Oncology Group; NCI |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01628380* | Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer | N/A |
| NCT00426257* | Secondary Debulking Surgery +/–Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer | N/A |
| NCT01802749* | Bevacizumab Beyond Progression in Platinum-Sensitive Ovarian Cancer | Bevacizumab; paclitaxel; carboplatin; pegylated liposomal doxorubicin; gemcitabine |
| NCT01654146* | ICON8: Weekly Chemotherapy in Ovarian Cancer | Carboplatin; paclitaxel |
| NCT01846611* | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Trabectedin; DOXIL; dexamethasone |
| NCT00565851* | Carboplatin, Paclitaxel, and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | Carboplatin; docetaxel; gemcitabine hydrochloride; paclitaxel |
| NCT01611766* | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? | Salvage chemotherapy |
| NCT01376752* | Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | Cytoreductive surgery and HIPEC; cytoreductive surgery alone | 94 | A.O. Ospedale Papa Giovanni XXIII; Clinical Organization for Strategies & Solutions (CLIOSS), former Nerviano Medical Sciences; Onlus Cancro Primo Aiuto |
| N/A | Secondary debulking with or without IP chemotherapy | 280 | The Netherlands Cancer Institute |
| N/A | N/A | 400 | National Cancer Institute, Naples; Mario Negri Institute for Pharmacological Research |
| N/A | N/A | 1,485 | Medical Research Council; Cancer Research UK |
| N/A | N/A | 670 | Janssen Research & Development, LLC; PharmaMar |
| Bevacizumab | LBA; QOL assessment | 1,038 | NCI |
| N/A | Secondary cytoreductive surgery | 420 | Shanghai Gynecologic Oncology Group; Fudan University; Zhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Sun Yat-sen University |
| N/A | Maximal cytoreductive surgery | 444 | UNICANCER |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT02446600* | Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Carboplatin; cediranib maleate; gemcitabine hydrochloride; olaparib; paclitaxel; pegylated liposomal doxorubicin hydrochloride |
| Phase IV Interventional Studies | ||
| NCT01706120 | Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin + Paclitaxel With Bevacizumab | Bevacizumab; paclitaxel; carboplatin |
| Interventional Studies (Phase Not Indicated) | ||
| NCT01747798 | Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Auranofin |
| NCT02096783 | Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer | N/A |
| NCT01696994 | Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) | N/A |
| NCT02595281 | HE4 as a Relapse Biomarker in Ovarian Cancers | N/A |
| NCT00946283 | Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome | N/A |
| NCT02578888* | Palliative Care in Improving QOL in Patients With High-Risk Primary or Recurrent Gynecologic Malignancies | N/A |
| NCT02013492* | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed by Surgery | Propranolol hydrochloride |
| NCT01442051* | Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | LBA; QOL assessment | 450 | NCI |
| N/A | N/A | 400 | National Cancer Institute, Naples; Mario Negri Institute for Pharmacological Research |
| N/A | LBA | 10 | Mayo Clinic |
| N/A | Informational intervention; counseling intervention; questionnaire administration | 30 | University of Wisconsin–Madison; NCI |
| N/A | Ultrasound imaging; screening questionnaire administration; LBA | 78,216 | NCI |
| N/A | Experimental arm | 90 | Institut de Cancérologie de Lorraine |
| N/A | Lactobacillus rhamnosus GG (dietary supplement) | 30 | Rutgers, The State University of New Jersey; NCI; Rutgers Cancer Institute of New Jersey |
| N/A | Palliative therapy; palliative therapy + idiographic | 180 | Albert Einstein College of Medicine of Yeshiva University; NCI |
| N/A | Correlative studies | 35 | William Carson; Ohio State University Comprehensive Cancer Center |
| N/A | Acute normovolemic hemodilution | 41 | Memorial Sloan Kettering Cancer Center |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT02530606* | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | N/A |
| NCT02412124* | Peer-to-Peer Support Program in Improving QOL Outcomes in Patients With Gynecologic Cancer and Their Caregivers | N/A |
| NCT02218502* | Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses | N/A |
| NCT01519869* | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | Neoadjuvant chemotherapy |
| NCT02477202* | Mirena® Intra-Uterine Device’s (IUD’s) Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation | N/A |
| NCT01230346* | Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | N/A |
| NCT02281487* | Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy | N/A |
| NCT01504126* | Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | Propranolol; chemotherapy |
| NCT02530606* | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | N/A |
| NCT02110277* | Photoacoustic Imaging of the Ovary | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | Photoacoustic imaging | 20 | Stanford University; NCI |
| N/A | Supportive care; QOL assessment; questionnaire administration | 30 | City of Hope Medical Center; NCI |
| N/A | Ultrasound by general gynaecologist; ultrasound by an expert ultrasonographist; DW-MRI; give blood sample | 270 | Maastricht University Medical Center; Laurentius Hospital Roermond; St. Jans Gasthuis Weert; VieCuri Medical Centre; Orbis Medical Centre |
| N/A | N/A | 28 | Rachel Miller; University of Kentucky |
| N/A | Mirena® IUD | 14 | Memorial Sloan Kettering Cancer Center |
| N/A | Questionnaire administration; survey administration; counseling intervention; educational intervention | 475 | City of Hope Medical Center; NCI |
| N/A | Hysterectomy with or without tubectomy; light microscopy | 100 | Gynaecologisch Oncologisch Centrum Zuid; St. Elisabeth Hospital, Tilburg, Netherlands; Catharina Ziekenhuis Eindhoven; Radboud University; Jeroen Bosch Ziekenhuis |
| N/A | Surgery; questionnaire | 25 | MD Anderson Cancer Center; Sprint for Life |
| N/A | Photoacoustic imaging | 20 | Stanford University; NCI |
| N/A | Photoacoustic imaging/ultrasound diagnostic group (device) | 40 | University of Connecticut Health Center; NCI |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01846520* | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II–IV Gastrointestinal, Gynecologic, and Urologic Cancers | N/A |
| NCT02082470* | Survivorship Care Planning in Improving QOL in Survivors of Ovarian Cancer | N/A |
| NCT02323568* | Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs | N/A |
| NCT02111941* | Vaccine Therapy in Treating Patients With Stage IIIC–IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy | N/A |
| NCT02039388* | Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma | N/A |
| NCT02376231* | To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC–Initial Feasibility Study | N/A |
| NCT02518256* | Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma–Study of Sensitivity and Specificity | N/A |
| NCT02062697* | Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes | N/A |
| Observational Studies | ||
| NCT01276574 | Epithelial Ovarian Cancer–Staging and Response to Chemotherapy Evaluated by PET/CT | Not indicated |
| NCT00899093 | Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | Educational intervention; telephone-based intervention; QOL assessment; questionnaire administration | 200 | City of Hope Medical Center; NCI; American Cancer Society National Office |
| N/A | Follow-up care; active surveillance; questionnaire administration | 20 | City of Hope Medical Center; NCI |
| N/A | Gynecological consultation | 120 | Centre Francois Baclesse; Ligue contre le cancer, France; Fondation de France |
| Multi-epitope folate receptor alpha-loaded dendritic cell vaccine | LBA | 22 | Mayo Clinic; NCI |
| N/A | Lavage of the cavum uteri and proximal fallopian tubes | 200 | Medical University of Vienna |
| N/A | Surgery for EOC with trial (PJ) device (PlasmaJet) | 150 | Thumuluru Kavitha Madhuri; Royal Surrey County Hospital; NHS Foundation Trust |
| N/A | 540 | Medical University of Vienna | |
| N/A | Lavage of the cavum uteri and proximal fallopian tubes; liquid-PAP smear | 50 | Medical University of Vienna |
| Not indicated | Not indicated | 150 | Turku University Hospital |
| N/A | LBA | 2,500 | Gynecologic Oncology Group; NCI |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01080521 | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy | N/A |
| NCT01295489 | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | IP chemotherapy |
| NCT00337233 | Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer | N/A |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | N/A |
| NCT00899496 | Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants | N/A |
| NCT02297958* | Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma | Not indicated |
| NCT02524808* | Prospective Identification and Validation of “BRCANess” Profile in Ovarian Epithelial Cancer | Not indicated |
| NCT00488878* | Data Collection for Patients With Low-Grade Ovarian Carcinoma | N/A |
| NCT01907789* | Prophylactic Salpingectomy With Delayed Oophorectomy | N/A |
| NCT01000259* | Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer | N/A |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| N/A | Cognitive assessment; QOL assessment | 256 | Gynecologic Oncology Group; NCI |
| N/A | Gene expression analysis; protein analysis; flow cytometry; immunoenzyme technique; immunohistochemistry staining method; LBA | 39 | Gynecologic Oncology Group; NCI |
| N/A | Yoga therapy | 106 | Comprehensive Cancer Center of Wake Forest University; NCI |
| N/A | Flow cytometry; LBA; data collection | 200 | Vanderbilt-Ingram Cancer Center; NCI; NIH |
| N/A | Immunological diagnostic method; physiologic testing | 48 | Comprehensive Cancer Center of Wake Forest University; NCI |
| Not Indicated | Not indicated | 40 | Rennes University Hospital |
| Not Indicated | Not indicated | 230 | Fundación de investigación HM; AstraZeneca |
| N/A | Data collection | 2,000 | MD Anderson Cancer Center |
| N/A | Ovarian cancer screening; prophylactic salpingectomy with delayed oophorectomy; risk-reducing salpingooophorectomy; questionnaire; transvaginal ultrasound; phone call | 80 | MD Anderson Cancer Center |
| N/A | LBA | 174 | Gynecologic Oncology Group; NCI |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT00628654* | Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants | Not indicated |
| NCT02315469* | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery | N/A |
| NCT01832415* | First-Line Ovarian Cancer Treatment–Cohort Study | Bevacizumab |
| NCT02394015* | Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC | Trabectedin and pegylated liposomal doxorubicin |
| NCT01445275* | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | N/A |
| NCT02073500* | Peritoneal Surface Malignancies–Characterization, Models and Treatment Strategies | N/A |
| NCT02489058* | A Study of Long-Term Responders on Olaparib | Not indicated |
| NCT02291276* | Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (Gyn Right)–Pilot Study | Not indicated |
| NCT01932125* | An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Not indicated |
| NCT02408536* | Observational Retrospective Study on Treatment and Outcomes in Patients With Low-Grade Serous Ovarian Cancer | Not indicated |
| NCT01703442* | Intraoperative Anuric Episodes in Patients Undergoing Laparotomy | Not indicated |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| Not indicated | Not indicated | 700 | University of California, Davis; NCI |
| N/A | Comprehensive geriatric assessment; questionnaire administration | 228 | NRG Oncology; NCI |
| N/A | N/A | 500 | ARCAGY/GINECO GROUP; Roche Pharma AG |
| N/A | N/A | 80 | Grupo Español de Investigación en Cáncer de Ovario; PharmaMar |
| N/A | Evaluation of cancer risk factors; medical chart review; study of socioeconomic and demographic variables | 2,605 | Gynecologic Oncology Group; NCI |
| N/A | Observational study | 200 | Oslo University Hospital; The Research Council of Norway |
| Not indicated | Not indicated | 100 | University Health Network, Toronto |
| Not indicated | Not indicated | 30 | Charite University, Berlin, Germany |
| Not indicated | Not indicated | 100 | Hoffmann-La Roche |
| Not indicated | Not indicated | 150 | National Cancer Institute, Naples |
| Not indicated | Not indicated | 25 | Claudia Spies; Charite University, Berlin, Germany |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| NCT Number | Title | Drug Intervention |
| NCT01982500* | Observation of Bevacizumab Plus Front-Line Chemotherapy in Patients With Ovarian Cancer | Not indicated |
| NCT00005095* | Specimen and Data Study for Ovarian Cancer Early Detection and Prevention | N/A |
| NCT02524808* | Prospective Identification and Validation of “BRCANess” Profile in Ovarian Epithelial Cancer | Not indicated |
| NCT02489058* | A Study of Long-Term Responders on Olaparib | Not indicated |
| NCT01703442* | Intraoperative Anuric Episodes in Patients Undergoing Laparotomy | Not indicated |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
| Biological Intervention | Other Intervention | Estimated Enrollment | Sponsor/Collaborators |
| Not indicated | Not indicated | 200 | Hellenic Oncology Research Group |
| N/A | LBA; screening questionnaire administration; study of high-risk factors | 6000 | Northwestern University; NCI |
| Not indicated | Not indicated | 230 | Fundación de investigación HM; AstraZeneca |
| Not indicated | Not indicated | 100 | University Health Network, Toronto |
| Not indicated | Not indicated | 25 | Claudia Spies; Charite University, Berlin, Germany |
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
Suggested Citation:"Appendix C: Open and Active Clinical Trials on Epithelial Ovarian Cancer." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press. doi: 10.17226/21841.
×
